Dupilumab Consistently Reduces CCL-17 (TARC) in Patients with Atopic Dermatitis Across All Age Groups

Elevated serum C-C motif chemokine ligand 17 (CCL17)/thymus and activation-regulated chemokine (TARC) has been associated with atopic dermatitis (AD) severity. Reductions in type 2 inflammatory biomarkers such as CCL17/TARC have been reported in adult patients with moderate-to-severe AD treated with dupilumab.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Lisa Beck, Mark Boguniewicz, Yoko Kataoka, Marjolein de Bruin-Weller, Antonella Muraro, Zhen Chen, Ainara Rodriguez-Marco, Parul Shah, Ana Rossi Source Type: research